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Abstract
This study aims to assess the oxidative stress in leprosy patients under multidrug therapy (MDT; dapsone, clofazimine and
rifampicin), evaluating the nitric oxide (NO) concentration, catalase (CAT) and superoxide dismutase (SOD) activities,
glutathione (GSH) levels, total antioxidant capacity, lipid peroxidation, and methemoglobin formation. For this, we analyzed
23 leprosy patients and 20 healthy individuals from the Amazon region, Brazil, aged between 20 and 45 years. Blood
sampling enabled the evaluation of leprosy patients prior to starting multidrug therapy (called MDT 0) and until the third
month of multidrug therapy (MDT 3). With regard to dapsone (DDS) plasma levels, we showed that there was no statistical
difference in drug plasma levels between multibacillary (0.51860.029 mg/mL) and paucibacillary (0.66260.123 mg/mL)
patients. The methemoglobin levels and numbers of Heinz bodies were significantly enhanced after the third MDT-
supervised dose, but this treatment did not significantly change the lipid peroxidation and NO levels in these leprosy
patients. In addition, CAT activity was significantly reduced in MDT-treated leprosy patients, while GSH content was
increased in these patients. However, SOD and Trolox equivalent antioxidant capacity levels were similar in patients with
and without treatment. These data suggest that MDT can reduce the activity of some antioxidant enzyme and influence
ROS accumulation, which may induce hematological changes, such as methemoglobinemia in patients with leprosy. We
also explored some redox mechanisms associated with DDS and its main oxidative metabolite DDS-NHOH and we explored
the possible binding of DDS to the active site of CYP2C19 with the aid of molecular modeling software.
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Introduction
Leprosy, also known as Hansen’s disease, is a chronic infectious
disease caused by Mycobacterium leprae. Leprosy remains a
significant public health problem in several parts of the world.
According to official reports submitted to World Health Organi-
zation (WHO) by 105 countries, the number of new cases detected
during the year 2011 was 219,075. Indeed, in 2012, 33,955 new
cases were detected in Brazil alone [1]. In this context; several
epidemiological studies have documented the main regions of
Brazil with a high prevalence of leprosy [2–4].
The current strategy for leprosy control recommended by the
WHO is based on multidrug therapy (MDT) that consists of the
combination of rifampicin, clofazimine and dapsone (DDS) for
multibacillary (MB) leprosy patients and rifampicin and dapsone
for paucibacillary (PB) leprosy patients [1]. DDS (4,49-diamino-
diphenylsulfone) has bacteriostatic action against Mycobacterium
leprae and is an essential component of MDT. The action of DDS
is due to inhibition of dihydrofolic acid synthesis by competition
with para-aminobenzoic acid (PABA) [5]. DDS distributes in all
body organs including skin, liver, kidneys, and erythrocytes, and
crosses the blood-brain barrier and the placenta, as well as being
found in breast milk [6]. DDS was initially used as an antibiotic in
humans at doses equivalent to sulfonamides, which led to severe
hemolytic anemia and methemoglobinemia [7,8].
Recently, our studies on the molecular structure/activity
properties of DDS showed that its biological properties are
strongly influenced by redox mechanisms associated with its
sulphone group as well as its nucleophilic aniline rings. Hence,
during the oxidative clearance of dapsone in man, hepatic CYPs
exploit the propensity of the molecule to undergo electron transfer
or oxidation to N-hydroxylated metabolites such as DDS-NHOH
and monoacetyl-hydroxylamine MADDS-NHOH [7–9]. Thus,
through its metabolically formed hydroxylated derivatives, DDS is
able to exert local oxidative stress conditions which impacts
macromolecules, such as proteins, lipids, carbohydrates and
nucleic acid, ultimately leading to cellular necrosis in patients
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[7,10]. The primary manifestation of the oxidative capacity of
dapsone-related hydroxylamines, is their induction of methemo-
globinemia in patients which may also lead to hemolysis [7].
Indeed, methemoglobin formation is caused by the co-oxidation of
the hydroxylamine metabolites, with oxyhemoglobin in erythro-
cytes [7,10]. In this study, we investigated the contribution of
multidrug therapy, which includes dapsone, towards the genera-
tion of oxidative stress and cell damage through the analysis of
antioxidant status (total antioxidant capacity, superoxide dismu-
tase and catalase activities), oxidative markers (nitric oxide levels,
lipoperoxidation, methemoglobin formation) and DDS levels in
patients with leprosy. The results were then associated with the
known redox mechanisms DDS and DDS-NHOH, through
molecular modeling studies. Whilst the role of the hydroxylamine
metabolites in dapsone toxicity is well established, the CYP
isoforms primarily responsible for their formation have been the
subject of considerable study in a variety of clinical and
experimental models over past decades; indeed, CYP3A4,
CYP2E1 and CYP2C9 [11–13] have each been postulated as
the major contributor to the oxidation of this drug. Latterly, a role
for CYP2C19, has been outlined in a study with recombinant
isoforms [14] and in our report we also explore the potential
interactions between dapsone and CYP2C19 using molecular
docking analysis.
Methods
Ethics statement
The Ethics Committee of the Federal University of Para´, Brazil,
approved the study protocol (protocol 079/09). It was also
approved by the State Reference Unit for Leprosy Treatment
Dr. Marcelo Candia, Marituba and Health unit Guama, Brazil
and so gave permission to start collecting data. All participants
were informed about the aims and methods of study and they also
wrote and signed the informed consent before the start of the
experiment and sample collection.
Population and experimental design
In this study, a total of forty-three subjects comprising twenty-
three patients diagnosed with leprosy, receiving care in the
Department of the State Reference Unit for Leprosy Treatment
under Dr. Marcello Candia- Marituba, and in the Health Unit of
Guama´, Bele´m, Para, Brazil. These patients were selected for the
study before starting multidrug therapy (called MDT 0) and they
were followed until the third month of multidrug therapy (MDT
3). Leprosy patients (age range, 20–45 years) were classified into
paucibacillary (PB; 9 cases) and multibacillary (MB; 14 cases),
based on WHO clinical criteria (testing positive for 2 of the 3
clinical criteria—skin lesions (#5, PB and .5, MB), anesthesia,
and nerve enlargement) and Bacteriological Index (BI) [1]. Two
slit-skin smears, one from a representative lesion and the other
from an earlobe, were obtained, and then stained using modified
Ziehl–Neelsen technique. A minimum of 100 oil-immersion fields
of the smear were examined for the presence of acid-fast bacilli,
and the BI was calculated.
Leprosy patients with reactions, ulceration, a history of smoking,
or those under the influence of alcohol, over 45 years of age, with
co-infections or diabetes mellitus or other systemic diseases or
health problems, and history of drug and nutraceutical use,
including vitamins, ascorbic acid, and tocopherol, were excluded
to rule out their possible influence on the study parameters. In this
study, patients were divided into two groups: samples collected
before administering the first dose MDT-supervised (MDT 0) and
after two months in the third dose MDT-supervised (MDT 3).
Healthy adults were selected voluntarily to serve as controls
(n = 20). This group did not have signs and symptoms of leprosy,
other diseases, or health problems, and the volunteers were
nonsmokers and free from drug use. The control group consisted
of sex-matched individuals, aged 20–45 years, who were living in
the same settings as those of the patients.
Blood samples (10 mL) were obtained from all participants by
venipuncture in tubes containing ethylenediaminetetraacetic acid
(EDTA). The whole blood samples were divided into two aliquots;
the first was used immediately for determining of MetHb and
GSH levels, activities of SOD and CAT and presence of Heinz
Bodies, whilst the second aliquot was centrifuged at 20006 g for
6 min, to separate plasma for the analyses of MDA and total
antioxidant status (TAS) levels as well as dapsone concentration
analysis. In addition, the serum was collected for NO measure-
ment (Figure 1).
DDS determination
The plasma concentrations of DDS were determined in
accordance with the procedures of extraction, quantification and
standardized by Kwadijk and Toran˜o [5], using High Perfor-
mance Liquid Chromatography (HPLC). The model used in the
chromatograph was ProStarVARIAN work with ODS RP18
column, 25 cm64 mm, UV detection at a wavelength of 295 nm
and flow 1 mL/min. As mobile phase we used aqueous solution of
30% acetonitrile and as internal standard, phenacetin solution of
100 mg/mL.
Determination of Methemoglobin (MetHb) Content
MetHb content was evaluated from the change in absorbance at
a wavelength of 632 nm; this change was caused by addition of
potassium cyanide (KCN) to the buffered hemolysate. A dilution of
the hemolysate, in which potassium ferricyanide (K3Fe(CN)6) was
used to convert all possible forms of hemoglobin (Hb) to MetHb,
was used as a reference solution. The MetHb content was
measured in duplicate, and values less than 2% were considered
normal [15].
Determination of Lipid Peroxidation
Lipid peroxidation was measured by quantifying MDA in blood
samples of patients using the thiobarbituric acid-reactive sub-
stances (TBARS) assay. This method is a very useful, economical,
Figure 1. Sampling procedure.
doi:10.1371/journal.pone.0085712.g001
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and easy-to-use assay for evaluating oxidative stress [16]. Briefly,
lipoproteins were precipitated by addition of samples to 0.05 M
trichloroacetic acid (TCA) and 0.67% TBA in 2 M sodium sulfate.
The union of lipid peroxide and TBA was performed by heating in
a water bath for 90 min. The chromogen formed was extracted in
n-butanol, which was measured at a wavelength of 535 nm. Lipid
peroxidation was expressed as nanomoles of MDA per liter.
Measurement of Total Antioxidant Status
The total antioxidant status (TAS) is a sensitive and reliable
marker to detect in vivo oxidative stress changes that may not be
detectable through the measurement of a single, specific antiox-
idant. In this study, the TAS was evaluated by Trolox equivalent
antioxidant capacity (TEAC). In this assay, 2, 2-azino-bis (3-
ethylbenzothiazoline, 6-sulfonate) (ABTS2) is incubated with
persulfate to produce ABTS+. This species is blue-green.
Antioxidants present in the sample cause a reduction in absorption
proportional to their concentration. The antioxidant capacities of
the samples are expressed as TEAC using a calibration curve
plotted with different amounts of Trolox and their absorbance
measured at 740 nm [17].
Determination of Nitric Oxide (NO)
The nitrate (NO3
2) present in the serum samples obtained from
the patients was reduced to nitrite using nitrate reductase, and the
nitrite concentration was determined by the Griess method [18].
Briefly, 100 mL of the serum supernatant was incubated with an
equal volume of the Griess reagent for 10 min at room
temperature. The absorbance was then measured on a plate
scanner (Spectra Max 250; Molecular Devices, Menlo Park, CA,
USA) at 550 nm. The nitrite (NO2
2) concentration was deter-
mined using a standard curve generated using sodium nitrate
(NaNO2). Nitrite production is expressed per mM.
Glutathione (GSH) Levels
Determination of the intracellular GSH levels was based on the
ability of GSH to reduce 5,5-dithiobis-2-nitrobenzoic acid (DTNB)
to nitrobenzoic acid (TNB), which was quantified by spectropho-
tometry at 412 nm. The methodology described by Ellman [19]
was adapted for this determination, and GSH concentrations were
expressed in mmol/mL. This assay was adapted for use in a
microtitre plate using a microplate spectrophotometer system,
Spectra MAX 250 (Molecular Devices, Union City, CA, USA)
[20].
Superoxide Dismutase (SOD) Activity
Determination of SOD activity was performed according to the
procedure recommended by McCord and Fridowich [21]. This
method evaluated the ability of SOD to catalyze the conversion of
O2
2 to H2O2 and O2. SOD activity was measured using UV
spectrophotometry at a wavelength of 550 nm and was expressed
in nmol/mL.
Catalase (CAT) Activity
Determination of CAT activity was performed according to the
procedure recommended by Bleuter [22]. We evaluated the ability
of the enzyme present in the sample to convert H2O2 to H2O and
O2. The decay of H2O2 was measured using ultraviolet
spectrophotometry at 240 nm, and CAT values were expressed
as units per gram of hemoglobin (U/g protein).
Presence of Heinz Bodies
The precipitation of protein aggregates from the cytoplasmic
membrane produces so-called Heinz bodies. Such inclusions can
be observed under an optical microscope by staining with crystal
violet or brilliant cresyl blue and visualized as globular inclusions
of approximately 3 mm. Laboratory analysis for the quantification
of Heinz bodies was based on the methodology employed by
Rimiolli and Godoy [15].
Statistical Analysis
Data are reported as the mean 6 SD values. Statistically
significant differences between groups were determined using
Analysis of Variance (ANOVA) followed by Tukey multiple
comparison tests. P,0.05 was considered statistically significant.
Molecular Docking
For studies of the interactions involving dapsone with the
biological macromolecule human microsomal cytochrome P450
(CYP) 2C19, we conducted a computer assisted virtual molecular
docking [23], which is one of the techniques of molecular
modeling, which consists of: predicting the bioactive conformation
of a micromolecule (ligand) at the site of a biological macromol-
ecule, followed by the evaluation and classification of the proposed
binding mode [24]. The structure of the human microsomal
CYP2C19 (4GQS, resolution 2.87 A˚) obtained from the crystal-
lographic protein data bank (PDB) and used in the study of
docking was resolved experimentally by X-ray crystallography
[25]. Prior to the study of virtual molecular docking, molecular
mechanics calculations were performed with the three-dimension-
al structure developed for dapsone, based on the force-field
MMFF94 [26], so that there would be a better accommodation of
the free atoms in the respective structure of dapsone. Computa-
tional tools for the performing of the virtual molecular docking
differ in the manner of dealing with the flexibility of the enzyme,
the ligand, its algorithm and scoring function [27]. In the present
study, the molecular docking algorithm chosen was MolDock [23].
The study was performed in the flexible docking mode, using the
scoring function of the docking algorithm, which is an extension of
the linear potential by parts (PLP), the spatial adjustment of a wide
variety of conformations of dapsone were tested at the catalytic
interaction site of CYP2C19 and several docking solutions were
generated automatically from the input structure of dapsone. The
accuracy of the docking was further improved by using the
algorithm rescoring function, which identified the most promising
docking solution among the solutions obtained by the docking
algorithm. We examined the complementarity of the interactions
of the CYP2C19-DDS complex formed and identified the results
that provided the best correlation between the poses and scores
obtained.
Results and Discussion
Demographic and laboratorial characteristics of patients
with leprosy
The final study cohort comprised 23 patients and 20 healthy
individuals (control). Of these patients, 39% were classified as PB
and 61% as MB. The twenty-three patients who initiated this
research before MDT (called MDT0) were followed up until the
third supervised dose of MDT (called MDT3). Most patients were
female (54%) with age varying from 20–30 years (55%), 29% had a
positive bacteriological index (BI) varying from degree 0.1–6, 39%
presented disability (1 or 2 scores), and 28% had nerve damage (1
to 3 scores). All healthy participants did not show BI, degree of
disability, or nerve damage (Table 1).
Oxidative Stress in Leprosy Patients
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Dosage of DDS
After implementation of MDT (dapsone in combination with
rifampicin and clofazimine) by WHO for the treatment of leprosy
in order to monitor and achieve global elimination of leprosy,
some adverse reactions, mainly caused by DDS, were observed in
these patients [7]. The use of dapsone may cause oxidative stress
leading to an imbalance between pro-oxidant and antioxidant
agents [7].
DDS mediated adverse reactions appear to be mainly due to its
N-hydroxylated metabolite, DDS-NHOH and the toxicity is dose-
dependent [7,28]. Thus, the therapeutic monitoring of drugs or
their metabolites is essential to promote dose adjustment in order
to control the therapeutic or toxic effects [28]. In this study, data
showed that MB patients after the third dose supervised (MDT3)
had a plasma concentration of dapsone of 0.51860.029 mg/mL,
while PB patients had 0.66260.123 mg/mL. There was no
significant difference between the dapsone concentrations in
patients with different clinical forms (p.0.05, Table 2).
These data were similar to that reported by Vieira et al. [28],
where 90% of patients presented therapeutic levels of dapsone of
0.5 to 5.0 mg/mL. Whilst some studies showed that concentrations
of this drug in the plasma of leprosy patients are variable; they
generally, remain within the accepted therapeutic range [7,28].
Moreover, the values obtained in this work do not correspond to
toxic concentrations. According to Carraza et al. [29], patients
who had taken between 4 and 7.5 tablets of dapsone (100 mg
each) had moderate to severe intoxication. In this regards, DDS
levels for mild intoxication were found in patients who had
average plasma concentrations up to 10 times the therapeutic level
(1 mg/mL) of this drug, while 10 to 21 times (10–21 mg/mL) were
moderate and over 21 times, constituted severe intoxication [30].
Although the liver is the major site of dapsone metabolism,
hepatotoxicity has been observed only when the dose exceeded
300 mg/day [31].
Oral DDS is absorbed readily from the gastrointestinal tract
with bioavailability of more than 86% [32]. After absorption, the
drug is transported through the portal circulation to the liver,
where it is metabolized via N-hydroxylation, acetylation or
glucuronidation. Moreover, the peak plasma concentration after
100 mg of oral dapsone is attained between 2 to 8 hours, and 85%
of it is excreted in the urine, primarily as glucuronides, and 10% in
the bile [32,33]. The long elimination half-life of dapsone
averaging between 24 and 30 hours is thought to be due to
several factors, such as significant enterohepatic recirculation,
relatively high plasma protein binding (70–90%) of the drug and
its acetylated metabolite (99%); indeed, the interconvertibility of
the acetylated and parent forms also extends drug residence time
[7,34].
Biomarkers of oxidative stress
To determine oxidative stress in leprosy patients under
treatment with MDT, we evaluated the systemic levels of nitric
oxide, lipid peroxidation and MetHb as indicative of damage, and
also the antioxidant status through the activities of SOD and CAT,
GSH levels and capacity total antioxidant by TEAC.
Hydroxylamines can be formed from the parent and the
acetylated derivative and they are potent oxidants which cause the
hematologic adverse effects associated with dapsone, including
methemoglobinemia and hemolytic anemia [7,10,34,35,36]. In
this regard, leprosy patients presented with significantly enhanced
MetHb percentage after the third dose supervised (MDT3), with
values above the normal range (,2%). Basal levels were equivalent
in untreated patients (MDT0) and healthy individuals (Figure 2b).
In relation to the presence of Heinz bodies, Table 3 shows that
only one of the untreated leprosy patients (MDT0 group)
presented with Heinz bodies, with 1 body in each 500 cells
counted, while an increased detection of the bodies was seen in
nine (39%) of the MDT-treated leprosy patients (MDT3 group)
(two or more bodies for each 500 cells analyzed).
Methemoglobin is generated from the oxidation of the heme
group of hemoglobin to the ferric state, (Fe2+ to Fe3+), and thus
cannot bind oxygen, levels which exceed 70% can result in patient
fatality [37]. Oxidants such as DDS metabolites as well as forming
methemoglobin, also generate other reactive species, such as
superoxide and hydrogen peroxide. Indeed, the intracellular
Table 1. Demographic and laboratorial characteristics of
leprosy patients and healthy individuals.
Variables Leprosy Cases n=23 (%) Control n=20 (%)
Gender (%)
Female 54 40
Male 46 60
Age
20–30 55 50
31–40 28 35
41+ 17 15
Bacteriological Index
0 44 100
0.1–2.0 06 00
2.1–4.0 17 00
4.1–6.0 06 00
unknown 27 00
Degree of disability
0 44 100
1 17 00
2 22 00
unknown 17 00
Nerves affected
0 33 100
1 06 00
2 11 00
3 11 00
unknown 39 00
doi:10.1371/journal.pone.0085712.t001
Table 2. Dapsone plasma concentrations determined in
samples of leprosy patients in multi-and paucibacillary clinical
forms according to the treatment time in months.
Treatment Time (months) DAPSONE CONCENTRATIONS (mg/mL)
Multibacillary Paucibacillary
MDT 0 ND ND
MDT 3 0,51860.029 0,66260.123
ND – Not detected; Samples collected before administering the first dose MDT-
supervised (MDT 0) and after two months in the third dose MDT-supervised
(MDT 3).
doi:10.1371/journal.pone.0085712.t002
Oxidative Stress in Leprosy Patients
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oxidative stress leads to the formation of soluble and insoluble
denaturation products of hemoglobin. The most apparent
insoluble products include Heinz bodies [38,39] reported that
the long-term treatment only with DDS (100 mg daily) or MDT
(dapsone in combination clofazimine and rifampicin) resulted in
clinically significant hemolysis and MetHb, although the use of
rifampicin and clofazimine, or clofazimine alone does not appear
to increase the incidence of MetHb during treatment.
In agreement with our report, Dalpino et al. [40] showed that
the percentage of MetHb of leprosy patients who were under
treatment of dapsone (100 mg/day) was increased significantly
compared to control. Regarding patient tolerance of DDS
therapy, generally, patients with MetHb rates below 10% do not
show any significant symptoms. However, a certain degree of
hemolysis during DDS therapy appears inevitable, as alongside
our present report, several previous studies have shown the
presence of Heinz bodies during therapy with this drug [15,41]. In
addition, Mahmud et al. [42] reported that the dapsone
(100 microM) was the most potent former of methaemoglobin in
human erythrocytes, and the substitution of the sulphone group
with sulphur, oxygen, nitrogen, carbon or a keto group in drug
resulted in a decrease in methaemoglobin formation.
Regarding nitric oxide production, we observed that their levels
were significantly higher in patients of both groups MDT0 and
MDT3 when compared to healthy individuals. However, there
was no difference between MDT-treated and untreated patients
(Figure 2a). These data showed that the disease process appears to
be responsible for the detected NO increase in the body, as shown
by our previous report [43] and other studies [44,45].
Free radicals can cause cellular damage and undesired lipid
peroxidation, which leads to the degradation of membrane lipid by
free radicals produced by MDA. Serum/plasma levels of MDA
provide some indication of the extent of f oxidative stress-related
lipid peroxidation and cellular damage [46]. MDA was measured
as an index of lipid peroxidation in the plasma of patients and
healthy individuals. In this respect, our data showed that treatment
with MDT did not alter the MDA levels in leprosy patients, as
values were similar to those of healthy individuals (Figure 2c). In
our report, we also observed that the MDA values in untreated or
MDT-treated leprosy patients were similar to the control group
(Figure 2c). These data suggest that MDT did not promote lipid
peroxidation and cellular damage in the blood samples of leprosy
patients. The elevated GSH contents observed in these patients
Figure 2. Determination of nitric oxide (NO) in serum (a),
percentage of blood methemoglobin (b) levels of malondial-
dehyde (MDA) in plasma (c) of patients with untreated leprosy
(MDT 0) and after the third dose supervised treatment (MDT 3).
Figures in the chart are expressed as mean6 SD. *p,0.05 compared to
MDT0 (ANOVA).
doi:10.1371/journal.pone.0085712.g002
Table 3. Presence of Heinz bodies in blood smears of
individuals in the study.
HEINZ BODIES
GROUP Negative Positive Total
n (%) n (%) n (%)
Control 20(100) 00(00) 20(100)
MDT 0 22 (96) 01(04) 23(100)
MDT 3 14 (61) 09(39) 23(100)
Samples collected before administering the first dose MDT-supervised (MDT 0)
and after two months in the third dose MDT-supervised (MDT 3).
doi:10.1371/journal.pone.0085712.t003
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may account for the normal levels of MDA in these patients after
treatment with MDT (Figure 3b). In this regard, we observed
similar levels between patients without treatment (MDT0) and
healthy individuals. However, after treatment (MDT3 group),
these patients showed significant increases in GSH values
compared to the MDT0 group (Figure 3b). This protective effect
of the thiol has also been demonstrated in animal models, where
rats treated with 40 mg/kg of DDS yielded GSH and MetHb
values significantly higher compared to control [47].
GSH is a powerful antioxidant and a cofactor in many
antioxidant enzyme reactions, so an increase in GSH levels may
be relevant to the regulation of the activities of antioxidant
enzymes that use GSH as a cofactor and thus the maintenance of
oxidative balance [48]. In addition, some studies have shown that
GSH is considered a potent inhibitor of lipid peroxidation process,
and thus regulates the MDA content. One of the mechanisms by
which GSH performs this protective function is by regulating the
activity of GSH-dependent enzymes, such as peroxidases and
peroxiredoxins, which result in reduction of intracellular oxidative
stress followed by inhibition of the mitochondrial pathway of
apoptosis induced by ROS [49].
Concerning antioxidant enzymes, SOD activity was significant-
ly reduced in samples from untreated leprosy patients (MDT0) and
after the third dose supervised (MDT3) when compared to control
group (Figure 3a). However, the basal CAT activity in untreated
leprosy patients (MDT0) was similar to control group; its activity
was significantly decreased by the treatment in leprosy patients
(Figure 3c). The enzyme CAT is a tetrameric heme protein and
mainly responsible for hydrogen peroxide degradation in aerobic
and anaerobic organisms [50]. In summary, treatment with MDT
led to a significant decrease in CAT activity in leprosy patients, but
did not alter the SOD activity compared to untreated patients.
These data were similar to other studies that reported that
untreated leprosy patients have decreased levels of SOD compared
to healthy individuals [51], and that even after the use of MDT,
the SOD levels remained low. These findings indicate that
oxidative stress related to the reduction of antioxidants and free
radical increase observed in these patients may also be caused by
Mycobacterium leprae, as reported in a previous study [43,51].
Furthermore, studies reported that reduction of CAT activity may
be associated with factors related to individuals, such as enzymatic
deficiencies due to genetic mutations or a reduced synthesis of this
Figure 3. Antioxidant capacity of blood samples from untreated patients with leprosy (MDT 0) and after the third dose of
supervised treatment (MDT 3). Concentration of superoxide dimutase (SOD) (a), reduced glutathione (GSH) (b), catalase (CAT) (c), Trolox
equivalent antioxidant capacity (TEAC) (d). Figures in the chart are expressed as mean 6 SD. *p,0.05 compared to MDT 0 (ANOVA).
doi:10.1371/journal.pone.0085712.g003
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enzyme by changes in their gene expression [52]. Many factors
have been reported that can affect the gene expression of CAT,
such as the presence of certain ions, cytokines and drugs [7]. In the
case of infection by M. leprae, this agent requires ions and/or
metals present in the host to regulate the expression of some of
their resistance factors negatively affecting the supply of these
compounds for the synthesis of metalloproteins such as CAT in the
host organism [53]. On the other hand, the use of MDT has
contributed to maintaining a framework of protection from
oxidative stress due to host response to the infection process by
M. leprae. In this sense, DDS metabolites possess oxidizing
properties; amplifying the generation of reactive species, reducing
of CAT activity and hemoglobin oxidation leading to formation of
methemoglobin and Heinz bodies.
The ability of multidrug therapy to induce the production of
free radicals can be compensated by antioxidant defense in leprosy
patients. Antioxidants are best supplied by a balanced diet, but
unfortunately leprosy patients are often of deprived socioeconomic
status [54]. The analysis of the antioxidant capacity (AC) can
provide some insight into the general biological antioxidant health
the body, since it detects the presence of enzymatic and non-
enzymatic antioxidants, instead of determining the concentrations
Figure 4. Representation of the CYP 2C19. Area covered (depicted
as light blue transparent solid surface) by the two internal cavities
(catalytic site cavity and adjacent cavity) of human microsomal
cytochrome P450 (CYP) 2C19 (brown). The heme prosthetic group is
represented in green and the molecule of dapsone in the color red (a).
Delimitation of the area occupied by the two internal cavities (catalytic
site cavity and adjacent cavity) of the CYP2C19 (b).
doi:10.1371/journal.pone.0085712.g004
Figure 5. Dapsone-CYP 2C19 complex. Dapsone is shown in
spheres and the target enzyme is colored from blue, starting from
terminal N, through the red, up until terminal C (a). Dapsone-catalytic
site CYP2C19 complex: Dapsone, the interacting amino acid residues
and heme prosthetic group present in the catalytic site of CYP2C19 are
displayed as sticks. The heme group and the dapsone are highlighted in
a green contour (b). Coordination and interaction of dapsone when
faced with the heme prosthetic group of the catalytic site of the
CYP2C19 (c).
doi:10.1371/journal.pone.0085712.g005
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of these antioxidants individually. In this sense, using the TEAC
method for evaluation of AC has been recommended to evaluate
various samples such as food, extracts and biological samples such
as plasma [55]. In our study, we observed that the treatment with
MDT did not alter the TEAC level in plasma of leprosy patients,
which presented high levels similar to that of untreated patients
(Figure 3d). Many proteins such as ceruloplasmin, transferrin, and
small molecule antioxidants such as non-protein thiols, vitamins C
and E, and uric acid contribute to the TEAC concentrations in
plasma [56].
Dapsone is oxidized by a number of CYPs [57] and it is likely
that several are involved in its oxidation. Although only a single
report has outlined the impact of CYP2C19 on dapsone oxidation,
we explored the ability of the drug to bind to this CYP isoform,
which is polymorphic and has significant clinical relevance in drug
clearance [58]. Analysis of the internal cavities of CYP 2C19
showed two main contiguous cavities, one acting as the catalytic
site (Figure 4a), which is in agreement with those described by
Reynald et al. [25]. DDS (depicted in red) binds to amino acid
residues and to the heme prosthetic group in the cavity of the
catalytic site, just below the heme prosthetic group, which is
depicted in green (Figure 4b). These two internal cavities are
associated the following characteristics: volume 1271.04 A˚3,
surface 112.44 A˚2, lipophilic surface 801.61 A˚2, depth 28.16 A˚2,
ellipsoid main axis c/a ratio 0.22, ellipsoid main axis b/a ratio
0.80 (Figures 4b and 5a). The characteristics of the functional
groups present in the cavities in relation to their relevant forces to
molecular interactions were: 19 hydrogen bond donors, 68
hydrogen bond acceptors, 1 metal, 50 hydrophobic interactions
and a hydrophobicity ratio in the order of 0.36. The amino acid
composition of the cavities in relation to the polarity and electrical
charge was distributed as follows: nonpolar amino acids ratio 0.57,
polar amino acid ratio 0.31, positive amino acids ratio 0.03 and
negative amino acid ratio 0.07.
The results of the virtual molecular docking study conducted
between dapsone and human microsomal CYP2C19, reveals the
reactive groups present in dapsone as well as the forces and types
of interactions existing between these reactive groups and the
amino acid residues present in chain A of the cytochrome studied.
Such data facilitates the understanding of the types of interactions
and binding forces existing between them. The analysis of the
interactions between dapsone and CYP 2C19 showed that DDS
was located in the cavity of the reactive site, positioned near the
iron atom of the heme prosthetic group (Figures 5b–c). The
interactions which exist between DDS, the amino acid residues
which contact it and the heme prosthetic group present in the
catalytic site of CYP2C19 as well as their respective alpha-carbon
positions in chain A are illustrated in Figure 5b.
The results of molecular docking analysis showed that several
amino acid residues in the active site cavity interact with DDS.
The main intermolecular interactions observed were the hydro-
phobic interactions, coexisting between dapsone and the respective
amino acid residues Val113A, Phe114A, Ala297A, Thr301A and
Leu366A which participate in the interactions, and also between
dapsone and the heme prosthetic group, and the interaction by
means of the hydrogen bond which exists between the hydrogen
bond donating amino group (-NH2) in DDS and carbonyl group
(CO) in amino acid residue Asp293A as the respecti8ve hydrogen
bond acceptor (Figure 6). It was evident also that the amino group
attached to one of the aromatic rings and positioned nearest to the
heme prosthetic group was able to interact with the existing iron
atom in the heme group (Figures 5b–c). Our results provide some
preliminary observations on the possible DDS oxidation mecha-
nism by CYP 2C19 for the production of DDS-NHOH.
Conclusions
In summary, our data showed that the treatment with MDT in
leprosy patients led to a decrease in enzymatic antioxidant systems
as CAT, alongside an increase in GSH, as well as a rise in MetHb
levels and Heinz bodies’ formations. This situation may occur in
consequence to an oxidant/antioxidant imbalance systemically,
which is caused by a combination of the infection process and
multidrug therapy in leprosy patients. The analysis of the
interactions between DDS and CYP2C19 has provided some
perspective for future investigations which might explore the role
of this CYP in dapsone oxidation in vivo, although it is likely that
the drug is cleared by multiple CYP isoforms in vivo.
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Figure 6. Interaction between dapsone, ligand-binding amino
acid residues and the heme prosthetic group present in the
catalytic site of CYP2C19 - The arrow represents the interaction
between the hydrogen bond donating amino group (-NH2) in
dapsone and the corresponding hydrogen bond acceptor
(carbonyl group (CO) in residue Asp293A), dashed orange
circular lines followed by dotted lines represent sites of
hydrophobic interactions coexisting between dapsone and
the respective binding residues (113A Val, Phe 114A, 297A Ala,
Thr301A, Leu366A) and also with the heme prosthetic group.
doi:10.1371/journal.pone.0085712.g006
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